ArticleScientific reports2026
Lappaconitine protects SH-SY5Y cells from TNF-α-induced mitochondrial apoptosis by blocking the Bax-dependent Caspase-3 signaling pathway.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ginkgolide B Attenuates 6-Hydroxydopamine-Induced Cellular Damage and Modulates Oxidant-Evoked CaCurrent issues in molecular biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lappaconitine (LA) is a diterpene alkaloid isolated from Aconitum species and has been used in traditional Chinese medicine as an analgesic. Previous studies have also suggested that LA exerts anti-inflammatory and immunomodulatory effects. Neuroinflammation and oxidative stress, both of which are associated with mitochondrial dysfunction and apoptosis, contribute to the development and maintenance of neuropathic pain. We hypothesized that LA may protect SH-SY5Y cells against inflammation- and apoptosis-associated injury. To investigate whether LA attenuates TNF-α-induced inflammatory injury and apoptosis in SH-SY5Y cells and to explore the potential mechanisms involved. SH-SY5Y cells were pretreated with LA (0.1 or 1 μM) for 24 h and subsequently exposed to TNF-α (10 ng/mL) for 12 h. Apoptosis, mitochondrial function, inflammatory cytokine production, and the expression of mitophagy-related proteins were assessed in LA-pretreated and non-pretreated cells. LA pretreatment (0.1 or 1 μM) reduced apoptosis in TNF-α-exposed SH-SY5Y cells, increased Bcl-2 expression, and decreased the expression of Bax, Caspase-3, and Caspase-9. LA pretreatment also suppressed NF-κB activation and reduced IL-1β and IL-6 production. In addition, LA preserved mitochondrial integrity, as indicated by maintenance of mitochondrial membrane potential, reduced cytochrome c release, and decreased ROS accumulation. The expression of the mitophagy-related proteins PINK1 and Parkin was also increased following LA pretreatment. LA attenuated TNF-α-induced inflammatory injury and apoptosis in SH-SY5Y cells. These protective effects were associated with modulation of apoptosis-related signaling, suppression of inflammatory responses, preservation of mitochondrial function, and increased expression of PINK1/Parkin-related proteins. These findings suggest that LA may exert neuroprotective effects under inflammatory conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.